"Within Arch, we've been looking at neurobehavioral and neurodevelopmental psychiatric disorders over the last 10 years and wondering: When is the right time? Clearly, there's an enormous unmet market need that's not, unfortunately, diminishing in any way. We were constantly looking to see if the science had progressed to the point where it made sense to start a company and take that bet."
Kristina Burow, managing director, Arch Venture, which led a $40 million series A round for Blackthorn Therapeutics Inc. to support its research into neurobehavioral disorders

"We have to get to a point where the innovations that we do create, whether they're in hepatitis C or immuno-oncology or the next phase of diabetes medicine, are viewed as valuable. The difference with heath care is that patients don't want a Corolla . . . they want the Tesla."
Bob McMahon, president of the U.S. market for Merck & Co. Inc., addressing the state of health care innovation at the 2016 Medical Innovation Summit sponsored by Cleveland Clinic Innovations

"The market in Australia is just too small to build a sustainable company, so that means thinking about how to position a product globally from day one."
Paul Kelly, partner and managing director of venture capital firm Oneventures